dapagliflozin + sitagliptin

**Dapagliflozin + sitagliptin** is an oral fixed-dose antidiabetic combination used for **type 2 diabetes mellitus**. It combines dapagliflozin, a selective sodium-glucose cotransporter 2 inhibitor that lowers plasma glucose by reducing renal glucose reabsorption and increasing urinary glucose excretion, with sitagliptin, a competitive dipeptidyl peptidase 4 inhibitor that prolongs endogenous incretin activity to increase glucose-dependent insulin secretion and suppress glucagon secretion. The complementary mechanisms can improve glycaemic control with a generally low intrinsic risk of hypoglycaemia, although hypoglycaemia risk may rise with concomitant insulin or insulin secretagogues. Fixed-dose products have been studied and marketed in multiple jurisdictions, including formulations such as sitagliptin 100 mg plus dapagliflozin 5 mg or 10 mg tablets. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05236998))

Brand names

Dapasita

Other names

dapagliflozin/sitagliptinsitagliptin + dapagliflozinsitagliptin/dapagliflozin